Requires prescriptions for certain patients to include patients' weight.
Impact
The implementation of A2744 is expected to reinforce standards in prescribing practices, particularly for younger patients who are vulnerable to dosage errors, which can have serious health implications. The bill aligns with current efforts to improve pediatric healthcare practices, as it emphasizes the importance of individualized treatment based on measurable factors like weight. Healthcare providers may need to adapt their prescription processes and might require training to incorporate this new standard consistently across their practices.
Summary
Assembly Bill A2744 requires that any prescription or order for medication issued by an authorized prescriber for patients who are 18 years of age or younger must include the patient's weight expressed in kilograms. This requirement is intended to promote more precise medication dosages, as pediatric prescriptions often depend on accurate weight measurements for determining dosages. By mandating this inclusion on prescriptions, the bill aims to enhance patient safety and ensure that young patients receive appropriate medication amounts based on their weight.
Contention
Several points of contention may arise regarding A2744. Critics may argue that the bill adds an administrative burden on healthcare providers and prescribers, especially in fast-paced clinical environments. There may also be concerns about how weighing procedures will be standardized in various healthcare settings, or if there could be discrepancies in measurements that could affect treatment. Additionally, some stakeholders might question whether the benefits of requiring weight on prescriptions justify the potential inconveniences and adjustments needed for implementation.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.